TITLE:
A Double-Blind Study to Evaluate the Safety and Pharmacokinetics of L-Ofloxacin (RWJ 25213) in Subjects With HIV Infection

CONDITION:
HIV Infections

INTERVENTION:
Levofloxacin

SUMMARY:

      To determine the safety and pharmacokinetics of L-ofloxacin (RWJ 25213) in patients with HIV
      infection.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: Male
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria

        Patients must have the following:

        HIV infection.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Active opportunistic infection or neoplasm.

          -  High likelihood of death during study.

          -  Significant ophthalmologic, renal, hepatic, cardiovascular, hematologic, neurologic,
             psychiatric,respiratory, or metabolic disease.

          -  Donation of > 1 unit blood or acute loss of blood within one month of study entry.

        Patients with the following prior conditions are excluded:

          -  History of opportunistic infection.

          -  Previous allergic reaction to ciprofloxacin, norfloxacin, or any other quinolone.

        Prior Medication:

        Excluded:

        Use of any investigational agent within 7 days of entry into study. Use of any medication
        within 3 days prior to entry (7 days for AZT). Alcohol or drug abuse.
      
